Nektar Therapeutics

NASDAQ: NKTR
$3.57
-$0.31 (-8.0%)
Closing price May 23, 2022
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Amazon.com, AngloGold Ashanti, Bank of America, General Electric, Walt Disney and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Carnival, Facebook, Freeport-McMoRan, Motorola Solutions and Procter & Gamble.
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.
The top analyst upgrades, downgrades and initiations seen on Friday, January 6, include Cognizant Technology Solutions, Etsy, GoPro, Illumina, Shake Shack and Travelers Companies.
With the busiest earnings week behind us, it appears some of the restriction windows at major U.S. corporations are starting to open up a little.
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see the highest amount of share count buying.
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
The Quantitative Strategies team at Jefferies closely monitors the index changes. 24/7 Wall St. screened the Jefferies list of stocks that will see major position adds for the rebalance. Some of them...
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the highest upside to their target...
The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have gleaned some interesting morsels that could be huge as the year wears on.
Piper Jaffray analyst have a list of top biotech stock picks that could bring big gains for investors. The look for high-conviction near-term binary events and lower conviction catalysts with...